Literature DB >> 19577871

Hepatitis B: liver fibrosis and hepatocellular carcinoma.

A S F Lok1.   

Abstract

Chronic hepatitis B virus (HBV) infection is estimated to be the cause of 55-60% of hepatocellular carcinoma (HCC) in the world. It has been estimated that up to 40% of HBV-related HCC occur in persons who do not have cirrhosis while almost all cases of hepatitis C virus (HCV)-related HCC occur in the setting of cirrhosis. Data on the performance of non-invasive tests for liver fibrosis in patients with hepatitis B are limited. FibroTest may be superior to the Forns index, APRI, Goteborg University Cirrhosis Index (GUCI) and Hui model in detecting significant fibrosis (Metavir>F2) or cirrhosis (Metavir F4) but an algorithm that uses APRI for screening, FibroTest for confirmation, and biopsy for indeterminate cases has the greatest accuracy. Liver stiffness correlates with fibrosis stages but may be influenced by necroinflammatory activity with falsely high values in patients with alanine aminotransferase (ALT) flares and falsely low values in patients with viral suppression and ALT normalization during antiviral therapy. Therefore, additional studies are needed to determine the clinical settings in which liver stiffness measurement can accurately predict liver fibrosis and to establish cutoff values for differentiating different stages of fibrosis or cirrhosis. These studies should also compare the performance of liver stiffness measurement with serum markers of fibrosis in patients with varying degrees of necroinflammation and in untreated patients as well as patients receiving antiviral therapy. Until recently, older age, male gender and cirrhosis were the major risk factors associated with HCC development. Recent studies showed that HBV replication status, HBV genotype and mutations in the basal core promoter region play an important role in HCC development. These data indicate that algorithms incorporating demographics, viral factors, degree of necroinflammation and extent of fibrosis may be more accurate in predicting the risk of HBV-related HCC than fibrosis staging alone.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19577871     DOI: 10.1016/j.gcb.2009.06.001

Source DB:  PubMed          Journal:  Gastroenterol Clin Biol        ISSN: 0399-8320


  20 in total

1.  Progress in non-invasive detection of liver fibrosis.

Authors:  Chengxi Li; Rentao Li; Wei Zhang
Journal:  Cancer Biol Med       Date:  2018-05       Impact factor: 4.248

Review 2.  Natural regression of fibrosis in chronic hepatitis B.

Authors:  Shogo Ohkoshi; Haruka Hirono; Kazuhiko Watanabe; Katsuhiko Hasegawa; Kenya Kamimura; Masahiko Yano
Journal:  World J Gastroenterol       Date:  2016-06-28       Impact factor: 5.742

Review 3.  Clinical application of liver stiffness measurement using transient elastography in chronic liver disease from longitudinal perspectives.

Authors:  Beom Kyung Kim; James Fung; Man-Fung Yuen; Seung Up Kim
Journal:  World J Gastroenterol       Date:  2013-03-28       Impact factor: 5.742

Review 4.  Resection of hepatitis B virus-related hepatocellular carcinoma: evolving strategies and emerging therapies to improve outcome.

Authors:  Gar-Yang Chau
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

5.  Characteristics and management of patients with chronic hepatitis B in an integrated care setting.

Authors:  Monika Sarkar; Valentina A Shvachko; Joanna B Ready; Mary Pat Pauly; Norah A Terrault; Marion G Peters; M Michele Manos
Journal:  Dig Dis Sci       Date:  2014-04-12       Impact factor: 3.199

Review 6.  Clinical utility of complex mutations in the core promoter and proximal precore regions of the hepatitis B virus genome.

Authors:  Young Min Park
Journal:  World J Hepatol       Date:  2015-01-27

7.  Validation of P2/MS for reflecting hepatic fibrosis in patients with hepatocellular carcinoma.

Authors:  Su Jong Yu; Jeong Hoon Lee; Goh Eun Chung; Chang Hoon Lee; Eun Ju Cho; Eun Sun Jang; Min Sun Kwak; Yoon Jun Kim; Jung Hwan Yoon; Ja June Jang; Hyo Suk Lee
Journal:  Korean J Hepatol       Date:  2010-12

8.  Reduction of liver stiffness by antiviral therapy in chronic hepatitis B.

Authors:  Keisuke Osakabe; Naohiro Ichino; Toru Nishikawa; Hiroko Sugiyama; Miho Kato; Shiho Kitahara; Senju Hashimoto; Naoto Kawabe; Masao Harata; Yoshifumi Nitta; Michihito Murao; Takuji Nakano; Hiroaki Shimazaki; Yuko Arima; Koji Suzuki; Kentaro Yoshioka
Journal:  J Gastroenterol       Date:  2011-08-06       Impact factor: 7.527

Review 9.  Identifying the targets for treatment of liver fibrosis and hepatocellular carcinoma from both Western medicine and Chinese medicine.

Authors:  Yuewen Gong
Journal:  Chin J Integr Med       Date:  2012-03-30       Impact factor: 1.978

10.  Clinical Predictors for Neutrophil-to-Lymphocyte Ratio Changes in Patients with Chronic Hepatitis B Receiving Peginterferon Treatment.

Authors:  Puo-Hsien Le; Kung-Hao Liang; Ming-Ling Chang; Chao-Wei Hsu; Yi-Cheng Chen; Chih-Lang Lin; Wey-Ran Lin; Ming-Wei Lai; Chau-Ting Yeh
Journal:  In Vivo       Date:  2017 Jul-Aug       Impact factor: 2.155

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.